Literature DB >> 22782192

[Medical therapy of lower urinary tract symptoms [corrected]].

F Strittmatter1, S Madersbacher, C G Stief, C Gratzke.   

Abstract

Male lower urinary tract symptoms (LUTS) include storage and voiding disorders and should be carefully evaluated before the start of any treatment. Medical therapy is directed at improving symptoms and reducing the risk of progression in order to improve quality of life and prevent complications, such as acute urinary retention, or the need for surgical intervention. Careful assessment of the individual complaints helps to identify the best drug which should be adapted to each individual patient's risk profile. At present, α(1)-adrenoreceptor inhibitors and 5-alpha reductase inhibitors and their combination form the gold standard for pharmacological treatment. In addition, anticholinergic agents are increasingly being used as monotherapy or in combination with α1-adrenocepetor inhibitors for patients with predominant storage disorders while phosphodiesterase 5 (PDE5) inhibitors may be suitable for patients suffering from LUTS and concomitant erectile dysfunction.

Entities:  

Mesh:

Year:  2012        PMID: 22782192     DOI: 10.1007/s00120-012-2943-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  53 in total

1.  Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

Authors:  J Curtis Nickel; Peter Gilling; Teuvo L Tammela; Betsy Morrill; Timothy H Wilson; Roger S Rittmaster
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

Review 2.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

Review 3.  A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder.

Authors:  Christopher R Chapple; Claus G Roehrborn
Journal:  Eur Urol       Date:  2006-02-17       Impact factor: 20.096

4.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

Review 5.  A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.

Authors:  Michael J Naslund; Martin Miner
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

Review 6.  Cernilton for benign prostatic hyperplasia.

Authors:  T Wilt; R Mac Donald; A Ishani; I Rutks; G Stark
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 7.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

Authors:  Gerald Andriole; Nicholas Bruchovsky; Leland W K Chung; Alvin M Matsumoto; Roger Rittmaster; Claus Roehrborn; David Russell; Donald Tindall
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

Review 8.  Terazosin for benign prostatic hyperplasia.

Authors:  T J Wilt; R W Howe; I R Rutks; R MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2002

9.  Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.

Authors:  K Höfner; M Burkart; G Jacob; U Jonas
Journal:  World J Urol       Date:  2007-09-29       Impact factor: 4.226

Review 10.  A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.

Authors:  J C Nickel; S Sander; T D Moon
Journal:  Int J Clin Pract       Date:  2008-10       Impact factor: 2.503

View more
  1 in total

1.  [New treatment strategies for male lower urinary tract symptoms].

Authors:  L F Arenas da Silva; M Schönthaler; F Cruz; C Gratzke; J Zumbe; A Stenzl; B Amend; K-D Sievert
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.